Coexpression network analysis coupled with connectivity map database mining reveals novel genetic biomarkers and potential therapeutic drugs for polymyositis.
Kai WangRujie ZhuJu LiZhongyuan ZhangXin WenHongwei ChenLingyun SunPublished in: Clinical rheumatology (2022)
We used WGCNA to observe all aspects of PM, which helped to elucidate the molecular mechanisms of PM onset and progression and provide candidate targets for the diagnosis and treatment of PM. Key Points • Four microarray datasets were analysed in patients with polymyositis and healthy controls, and VCAM1 and LY96 were significant genes in all datasets. • GSEA of VCAM1 and LY96 revealed that they were mainly related to 'inflammatory response', 'TNF-α signalling via NF-κB', 'complement' and 'myogenesis'. • CMap found a few compounds such as dimethyloxalylglycine and HNMPA-(AM)3 with the potential to counteract the effects of the dysregulated molecular signature in PM.
Keyphrases
- particulate matter
- network analysis
- air pollution
- polycyclic aromatic hydrocarbons
- inflammatory response
- heavy metals
- water soluble
- lps induced
- interstitial lung disease
- genome wide
- signaling pathway
- rheumatoid arthritis
- rna seq
- single cell
- oxidative stress
- risk assessment
- gene expression
- functional connectivity
- resting state
- cell adhesion
- human health
- transcription factor
- high density
- electronic health record